JR-171
DrugIntravenous (IV) infusion
Other names: lepunafusp alfa
NCT Number: NCT04453085
Phase I/II, open label, multicenter, multinational (Japan, Brazil and the US) extension study of JR-171-101 (NCT04227600) for the treatment of MPS I
Looking for future studies?
Notify MeAll sexes
Interventional
Phase 1 / Phase 2
Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
Patients who have completed the Part2 of JR-171-101 study (NCT04227600) and fulfill all eligibility criteria can be enrolled in this JR-171-102 study. In the JR-171-102 study, subjects will receive either 2.0 or 4.0 mg/kg/week of JR-171 intravenously at the same doses received at Week 12 of the JR-171-101 study.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Intravenous (IV) infusion
Other names: lepunafusp alfa
Time frame: 156 weeks
Adverse events
Time frame: 156 weeks
Hematology
Time frame: 156 weeks
Biochemistry
Time frame: 156 weeks
Serum iron tests
Time frame: 156 weeks
Urinalysis
Time frame: 156 weeks
Pulse rate
Time frame: 156 weeks
Body temperature
Time frame: 156 weeks
Blood pressure
Time frame: 156 weeks
Body weight
Time frame: 156 weeks
Time frame: 156 weeks
Anti-human-α-L-iduronidase antibodies
Time frame: 156 weeks
Anti-JR-171 antibodies
Time frame: 156 weeks
Infusion associated reaction (IAR)
Time frame: Weeks 26, 52, 104, 156
Time frame: Weeks 26, 52, 104, 156
Time frame: Weeks 26, 52, 104, 156
Time frame: Weeks 13, 26, 39, 52, 65, 78, 91, 104, 130, 156
Time frame: Weeks 13, 26, 39, 52, 65, 78, 91, 104, 130, 156
Time frame: Weeks 13, 26, 39, 52, 65, 78, 91, 104, 130, 156
Time frame: Weeks 13, 26, 39, 52, 65, 78, 91, 104, 130, 156
Time frame: Weeks 13, 26, 52, 78, 104, 156
Time frame: Weeks 13, 26, 52, 78, 104, 156
Time frame: Weeks 13, 26, 52, 78, 104, 156
Left ventricular posterior wall thickness
Time frame: Weeks 13, 26, 52, 78, 104, 156
interventricular septal thickness
Time frame: Weeks 13, 26, 52, 78, 104, 156
left ventricular mass index
Time frame: Weeks 13, 26, 52, 78, 104, 156
left ventricular ejection fraction
Time frame: Weeks 13, 26, 52, 78, 104, 156
left ventricular ejection fraction,
Time frame: Weeks 13, 26, 52, 78, 104, 156
E/A ratio
Time frame: Weeks 13, 26, 52, 78, 104, 156
Time frame: Weeks 52, 104, 156
Wechsler Intelligence Quotient (IQ) test or the Bayley scales of infant and toddler development
Time frame: Weeks 52, 104, 156
Vineland adaptive behavior scales
Time frame: Weeks 13, 26, 52, 78, 104, 130, 156
Time frame: Weeks 13, 26, 52, 78, 104, 130, 156
Time frame: Weeks 13, 26, 52, 78, 104, 130, 156
Time frame: Weeks 13, 26, 52, 104 156
JCR Pharmaceuticals Co., Ltd.
Industry
An Extension Study of JR-171-101 Study in Patients With Mucopolysaccharidosis Type I
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05134571
Carbohydrate Metabolism, Inborn Errors, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Beijing, China
View Trial DetailsNCT05687474
3-Hydroxy 3-Methyl Glutaric Aciduria, 3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency
Liège, Wallonia, Belgium
View Trial DetailsNCT04227600
Carbohydrate Metabolism, Inborn Errors, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Oakland, California, United States
View Trial DetailsNCT00695279
Carbohydrate Metabolism, Inborn Errors, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Memphis, Tennessee, United States
View Trial Details